AbbVie Reports Favorable Phase 1 Results for ABBV-295 Long-Acting Amylin Analog in Adults

AbbVie has released topline results from a Phase 1 multiple ascending dose study evaluating ABBV-295, a long-acting amylin analog, in adults. The study aimed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABBV-295 across various dosage levels. According to the company, the findings demonstrated favorable outcomes in these areas.

The Phase 1 trial involved adult participants who received multiple ascending doses of ABBV-295. Researchers monitored key metrics such as adverse events, drug absorption rates, and biological responses to determine its potential efficacy and safety profile. AbbVie reported that the treatment was well-tolerated across all tested doses and showed promising pharmacodynamic effects consistent with its intended mechanism of action. Further studies are planned to evaluate its therapeutic potential in broader populations.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 9, 2026

Author

GOAI